Precigen (PGEN) Other Non-Current Assets (2012 - 2026)
Precigen (PGEN) reported Other Non-Current Assets of $782000.0 for Q1 2026, up 83.14% year-over-year from $427000.0 in Q1 2025, and down 13.88% quarter-over-quarter from $908000.0 in Q4 2025.
Precigen (PGEN) Other Non-Current Assets (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Other Non-Current Assets data on file, last reported at $782000.0 in Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $782000.0, up 83.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $782000.0 (up 83.14% YoY), and the FY2025 annual result was $908000.0, up 144.74% from the prior year.
- Other Non-Current Assets retreated to $782000.0 in Q1 2026 per PGEN's latest filing, from $908000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $44.3 million in Q2 2022 and troughed at $371000.0 in Q4 2024.
- A 5-year average of $3.5 million and a median of $774500.0 in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets surged 402990.91% in 2022, then sank 97.86% in 2023.
- A 5-year view of Other Non-Current Assets shows it stood at $1.0 million in 2022, then fell by 25.17% to $767000.0 in 2023, then tumbled by 51.63% to $371000.0 in 2024, then jumped by 144.74% to $908000.0 in 2025, then slipped by 13.88% to $782000.0 in 2026.
- Business Quant data shows PGEN's Other Non-Current Assets at $782000.0 in Q1 2026, $908000.0 in Q4 2025, and $753000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Precigen | 1.32 Bn | 1.32 Bn | 20.69 Mn | 782,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 782,000.00 |
| Dec 31, 2025 | 908,000.00 |
| Sep 30, 2025 | 753,000.00 |
| Jun 30, 2025 | 590,000.00 |
| Mar 31, 2025 | 427,000.00 |
| Dec 31, 2024 | 371,000.00 |
| Sep 30, 2024 | 425,000.00 |
| Jun 30, 2024 | 435,000.00 |
| Mar 31, 2024 | 751,000.00 |
| Dec 31, 2023 | 767,000.00 |
| Sep 30, 2023 | 797,000.00 |
| Jun 30, 2023 | 949,000.00 |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2022 | 1.03 Mn |
| Jun 30, 2022 | 44.34 Mn |
| Mar 31, 2022 | 1.13 Mn |
| Dec 31, 2021 | 936,000.00 |
| Jun 30, 2021 | 11,000.00 |
| Mar 31, 2021 | 1.43 Mn |
| Dec 31, 2020 | 9.85 Mn |